Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • A-769662: Potent Small Molecule AMPK Activator for Energy...

    2026-03-14

    A-769662: Benchmark Small Molecule AMPK Activator for Metabolic and Proteasome Research

    Executive Summary: A-769662 (APExBIO, A3963) is a potent, reversible small molecule AMPK activator with an in vitro EC50 of 0.8–0.116 μM. It activates AMPK allosterically and inhibits Thr-172 dephosphorylation, resulting in enhanced kinase activity and downstream inhibition of anabolic processes (e.g., fatty acid and cholesterol synthesis) while promoting catabolism (e.g., fatty acid oxidation, glycolysis) (https://doi.org/10.1038/s41467-023-38401-z). In primary rat hepatocytes, it inhibits fatty acid synthesis (IC50: 3.2 μM) and induces acetyl-CoA carboxylase (ACC) phosphorylation. In vivo, 30 mg/kg oral dosing reduces plasma glucose by ~40% and suppresses hepatic gluconeogenic enzymes. Recent mechanistic findings reveal that, contrary to older models, AMPK activation by A-769662 suppresses autophagy initiation through inhibition of ULK1, clarifying its role in energy stress response (https://doi.org/10.1038/s41467-023-38401-z). A-769662 also inhibits the 26S proteasome via an AMPK-independent pathway, offering dual utility for metabolic and proteostasis studies.

    Biological Rationale

    AMP-activated protein kinase (AMPK) is a serine/threonine kinase essential for cellular energy homeostasis. It senses cellular AMP:ATP ratios and modulates metabolic pathways to restore energy balance. During energy stress (e.g., glucose starvation, mitochondrial dysfunction), AMPK activation shifts cells toward ATP-generating catabolic processes and away from ATP-consuming anabolic processes. This regulatory axis underlies interest in small molecule AMPK activators like A-769662 for disease models such as type 2 diabetes and metabolic syndrome. Recent work demonstrates that AMPK activation also modulates autophagy, with nuanced effects on ULK1 and autophagosome formation (https://doi.org/10.1038/s41467-023-38401-z).

    Mechanism of Action of A-769662

    • Allosteric AMPK Activation: A-769662 binds the β1 subunit of AMPK, allosterically activating the kinase and increasing its activity even under low AMP conditions (https://doi.org/10.1038/s41467-023-38401-z).
    • Prevention of Thr-172 Dephosphorylation: The compound inhibits dephosphorylation of AMPK at Thr-172, sustaining kinase activation (https://doi.org/10.1038/s41467-023-38401-z).
    • Downstream Effects: Activated AMPK phosphorylates targets such as ACC, leading to inhibition of fatty acid synthesis and stimulation of fatty acid oxidation and glycolysis.
    • Proteasome Inhibition: A-769662 inhibits the 26S proteasome independently of AMPK, resulting in cell cycle arrest without affecting 20S core proteolytic activity (https://www.apexbt.com/a-769662.html).

    Evidence & Benchmarks

    • A-769662 activates AMPK in vitro with EC50 values between 0.8 and 0.116 μM, depending on assay conditions (Park et al., 2023).
    • In primary rat hepatocytes, A-769662 inhibits fatty acid synthesis with an IC50 of 3.2 μM and induces ACC phosphorylation dose-dependently (Park et al., 2023).
    • Oral administration of 30 mg/kg in mice reduces plasma glucose by ~40% and downregulates hepatic gluconeogenic enzymes (FAS, G6Pase, PEPCK) (Park et al., 2023).
    • A-769662 suppresses autophagosome formation by inhibiting ULK1, revising the canonical model of AMPK-induced autophagy (Park et al., 2023).
    • The compound inhibits the 26S proteasome via an AMPK-independent mechanism, causing cell cycle arrest but not affecting 20S proteasome activity (APExBIO product page).

    Compared to prior reviews (see here), this article incorporates recent mechanistic clarifications regarding AMPK’s dual regulatory roles, especially its suppressive effect on autophagy via ULK1 inhibition, updating the canonical view. For an integrative discussion of translational research strategies, see A-769662 and the AMPK Paradox, which this article refines by focusing on experimental controls and quantitative benchmarks. For a broader perspective on AMPK’s complexity, see this review; here, we provide updated consensus on the functional boundaries of A-769662.

    Applications, Limits & Misconceptions

    A-769662 is widely used in metabolic, autophagy, and proteostasis research:

    • Tool for dissecting AMPK signaling in cell and animal models of metabolic syndrome and type 2 diabetes.
    • Benchmark for evaluating fatty acid synthesis inhibition and ACC phosphorylation.
    • Used to differentiate AMPK-dependent vs. independent mechanisms in proteasome regulation.
    • Translational studies modeling energy metabolism and glucose homeostasis.

    Common Pitfalls or Misconceptions

    • Misconception: AMPK activation by A-769662 universally stimulates autophagy. Fact: Recent evidence shows A-769662 suppresses autophagy initiation via ULK1 inhibition (Park et al., 2023).
    • Misconception: All effects of A-769662 are AMPK-mediated. Fact: The compound inhibits the 26S proteasome independently of AMPK (APExBIO).
    • Misconception: A-769662 is effective in all cell types. Fact: Its efficacy depends on the expression of the AMPK β1 subunit; some cell lines may show attenuated response (Park et al., 2023).
    • Misconception: A-769662 is soluble in water. Fact: It is insoluble in water and ethanol and should be dissolved in DMSO (>18 mg/mL) (APExBIO).

    Workflow Integration & Parameters

    • Compound Handling: Store A-769662 powder at -20°C. Prepare solutions in DMSO, use within short-term window to maintain integrity (APExBIO).
    • Cell Culture: Typical in vitro concentrations range from 0.5–10 μM, depending on cell type and desired AMPK activation.
    • In Vivo Studies: Oral dosing in mice at 30 mg/kg achieves robust AMPK activation and metabolic effects; monitor plasma glucose and hepatic enzyme expression for efficacy (Park et al., 2023).
    • Readouts: ACC phosphorylation, fatty acid synthesis inhibition, glucose levels, and proteasome activity are recommended endpoints.
    • Controls: Include AMPK inhibitors or knockouts to confirm pathway specificity.

    Conclusion & Outlook

    A-769662 (APExBIO) is a chemically well-defined, potent tool compound enabling precise mechanistic and translational studies in AMPK signaling, energy metabolism, and proteostasis. Its dual activity profile, clarified by recent mechanistic advances, supports its use in modeling metabolic syndrome, type 2 diabetes, and cellular stress responses. Researchers should note updated insights regarding AMPK-autophagy crosstalk and the compound's AMPK-independent effects. For comprehensive protocols and ordering, see the A-769662 product page.